SMMT — Summit Therapeutics · catalysts, narrative & risks

Overview

Summit Therapeutics (NASDAQ: SMMT), a Miami-based biotech, is approaching a binary regulatory milestone with its stock trading at roughly US$15.08 as of the November 12, 2026 close, down 9.41% that day [13], [16], [17]. Note that two other November references cite a higher price of about US$17.84 [7], [8], which suggests the shares have fallen materially (roughly 15%+) in mid-November — plausibly due to de-risking ahead of the PDUFA, or profit-taking after the stock's multi-year run. Below is a point-in-time picture as of November 13, 2026.

Recent catalysts (last ~1–3 months)